tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Li PK et al. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. 1990 Adverse Drug React Acute Poisoning Rev pmid:1703724
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Thomson AW FK-506 enters the clinic. 1990 Immunol. Today pmid:1692221
Saitoh Y et al. Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. 1990 Jpn J Surg pmid:1692892
Rosen MK et al. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. 1990 Science pmid:1693013
Justice RM et al. The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. 1990 Biochem. Biophys. Res. Commun. pmid:1697463
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia. 1990 Life Sci. pmid:1698241
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Miyagawa J et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990 Diabetologia pmid:1698679
Lagodzinski Z et al. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. 1990 Immunology pmid:1698713
Mattila PS et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. 1990 EMBO J. pmid:1702384
Kawashima H et al. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. 1990 Invest. Ophthalmol. Vis. Sci. pmid:1702408
Wilkinson PC and Watson EA FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. 1990 Immunology pmid:1702750
Metcalfe S and Milner J Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. 1990 Immunol. Lett. pmid:1702753
Takada K et al. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. 1990 J. Chromatogr. pmid:1703552
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987
Fung JJ et al. Overview of FK506 in transplantation. 1990 Clin Transpl pmid:1715740
Pugh-Humphreys RG et al. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. 1990 Immunology pmid:1696242
Wasik M et al. Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. 1990 Jul-Aug Immunopharmacology pmid:1699911
MacLeod AM and Thomson AW [FK-506. A new immunosuppressive drug]. 1990 Jul-Sep Medicina (Firenze) pmid:1706817
Naouri A and Tissot E [Indications for liver transplantation in adults]. 1990 Jun-Jul J Chir (Paris) pmid:1698800
Gailliot FP et al. Fluidized bed adsorption for whole broth extraction. 1990 Sep-Oct Biotechnol. Prog. pmid:1366874
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
Takaori K et al. Effects of FK 506 on in vivo immunity in comparison to cyclosporine. 1991 Transplant. Proc. pmid:1721322
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Keicho N et al. Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. 1991 Cell. Immunol. pmid:1703047
de Paulis A et al. Characterization of the anti-inflammatory effect of FK-506 on human mast cells. 1991 J. Immunol. pmid:1721644
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Masaoka T et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721417
Ziccardi VB et al. Maxillofacial considerations in orthotopic liver transplantation. 1991 Oral Surg. Oral Med. Oral Pathol. pmid:1704494
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Sigal NH et al. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. 1991 Transplant. Proc. pmid:1712132
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
Jiang H et al. Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. 1991 Eur Surg Res pmid:1723683
Pezze JL and Whiteman K Transplantation's newest weapon FK 506. 1991 Am J Nurs pmid:1716857
Liu J et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. 1991 Cell pmid:1715244